Sathe, A <br/><br/>
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.  [electronic resource] 

 -  British journal of cancer  Nov 2014 
 - 2103-13 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2014.534  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Chickens<br/>Chorioallantoic Membrane<br/>Class I Phosphatidylinositol 3-Kinases<br/>Dual Specificity Phosphatase 1--physiology<br/>Extracellular Signal-Regulated MAP Kinases--metabolism<br/>Heterocyclic Compounds, 3-Ring--pharmacology<br/>Humans<br/>Molecular Targeted Therapy<br/>Mutation<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphorylation<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Urinary Bladder Neoplasms--drug therapy